Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Communication Strategies. Case Studies. Applied Knowledge.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 31 July 2018 | By Michael Mezher
The US Food and Drug Administration (FDA) has published the user fee amounts it will collect in FY2019 from the manufacturers of pharmaceuticals, generic drugs, biosimilars, medical devices and outsourcing facilities that produce compounded drugs. The table below lists the fees for each program:
Applications:
Requiring clinical data
$2,588,478
$2,421,495
Not requiring clinical data
$1,294,239
$1,210,748
Program fee
$309,915
$304,162
Abbreviated new drug application (ANDA)
$178,799
$171,823
Drug master file (DMF)
$55,013
$47,829
Facilities:
Active pharmaceutical ingredient (API) – Domestic
$44,226
$45,367
API – Foreign
$59,226
$60,367
Finished dosage form (FDF) – Domestic
$211,305
$211,087
FDF – Foreign
$226,305
$226,087
Contract manufacturing organization (CMO) – Domestic
$70,435
$70,362
CMO – Foreign
$85,435
$85,362
GDUFA program:
Large size operation generic drug applicant
$1,862,167
$1,590,792
Medium size operation generic drug applicant
$744,867
$636,317
Small business operation generic drug applicant
$186,217
$159,079
Initial biological product development (BPD)
$185,409
$227,213
Annual BPD
Reactivation
$370,818
$454,426
$1,746,745
$873,373
Program
Premarket application (a PMA submitted under section 515(c)(1) of the FD&C Act (21 U.S.C. 360e(c)(1)), a PDP submitted under section 515(f) of the FD&C Act (21 U.S.C. 360e(f), or a BLA submitted under section 351 of the Public Health Service Act (the PHS Act) (42 U.S.C. 262))
$322,147 ($80,537)
$310,764 ($77,691)
Premarket report (submitted under section 515(c)(2) of the FD&C Act)
Efficacy supplement (to an approved BLA under section 351 of the PHS Act)
Panel-track supplement
$241,610 ($60,403)
$233,073 ($58,268)
De novo classification request
$96,644 ($24,161)
$93,229 ($23,307)
180-day supplement
$48,322 ($12,081)
$46,615 ($11,654)
Real-time supplement
$22,550 ($5,638)
$21,753 ($5,438)
510(k) premarket notification submission
$10,953 ($2,738)
$10,566 ($2,642)
30-day notice
$5,154 ($2,577)
$4,972 ($2,486)
513(g) request for classification information
$4,349 ($2,175)
$4,195 ($2,098)
Annual fee type
Annual fee for periodic reporting on a class III device
$11,275 ($2,819)
$10,877 ($2,719)
Annual establishment registration fee
$4,884 ($4,884)
$4,624 ($4,624)
Qualified small business establishment fee
$5,461
$5,364
Non-small business establishment fee
$18,375
$17,364
Re-inspection fee
$16,382
$16,093
Federal Register: PDUFA, GDUFA, BsUFA, MDUFA, Outsourcing Facilities